ClinicalTrials.gg
RecruitingNCT07187583Updated Sep 23, 2025

Tapering of Biologics in Chronic Rhinosinusitis With Nasal Polyps

A Phase 4 interventional study of increased dosing interval of biological therapy in Chronic Rhinosinusitis With Nasal Polyps, sponsored by Rigshospitalet, Denmark. Recruiting at 9 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-23.

Sponsored by Rigshospitalet, Denmark · Phase 4, Interventional, and Treatment

How we know · 2 judgments

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jun 2025, registered Sep 2025).
  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Nasal Polyps with a site in Denmark — 5 open to participants now, 6 under way, 2 of them phase 3. Nasal Polyps · Denmark.

Started
2025
with 2 others
Phase 4
2 of 10
2 open now
Registered
9th of 10
by date
Lead sponsor
3 of 10
Rigshospitalet, Denmark

Among the 10 studies in Nasal Polyps with a site in Denmark, this one is one of 3 that started in 2025, is one of 2 in phase 4, and was the 9th registered.

Nasal Polyps

236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.

Browse Nasal Polyps studies →

Open to participants now

5 of the 10 studies in Nasal Polyps with a site in Denmark are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Nasal Polyps with a site in Denmark, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the feasibility of extending the dosing intervals of biological therapies while maintaining optimal treatment effects in chronic rhinosinusitis with nasal polyps (CRSwNP).

Read the detailed description

This is an investigator-initiated, independent, national multicenter study with a real-world design and Good Clinical Practice (GCP) monitoring. The study is a randomized controlled drug trial investigating the non-inferiority of extended dosing intervals compared with standard treatment for patients with CRSwNP receiving mepolizumab (100 mg) or dupilumab (300 mg) every 4 weeks. Approximately 135 patients will be enrolled from ear, nose and throat departments in all five regions of Denmark. The study duration is approximately 2.5 years, with each patient followed for 52 weeks.

Randomization At inclusion, patients are randomized 1:1 to the intervention or control group. Randomization is computer-based (REDCap).

Control group Continues dosing of mepolizumab or dupilumab every 4 weeks.

Intervention group Increases to a 6-week dosing interval at baseline, and if response to the biological therapy is maintained, increases to 8-week dosing intervals at the follow-up visit at week 26. Thereafter, dosing every 8 weeks is maintained until the patient completes the trial at week 52. In case of worsening of CRSwNP-related symptoms, the patient reverts to the last effective dosing interval.

Clinical visits Clinical follow-ups are conducted at weeks 0, 12, 26, 38, and 52. The visits at weeks 0, 26, and 52 are already planned as a standard part of biological treatment outside the protocol and include endoscopic rhinoscopy, smell testing, and questionnaires: Sinonasal Outcome Test 22 (SNOT-22), Work Productivity and Activity Impairment (WPAI), and Asthma Control Questionnaire (ACQ). The visits at weeks 12 and 38 are study-specific and include patient-reported symptom severity on a Visual Analogue Scale (VAS), endoscopic rhinoscopy, and completion of questionnaires (SNOT-22, WPAI).

03

Conditions studied

  • Chronic Rhinosinusitis With Nasal Polyps
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥18 years of age.
  • Currently receiving treatment with either dupilumab (300 mg) or mepolizumab (100 mg) every four weeks.
  • Having received the biologic at unchanged dosing interval for at least three months.
  • For at least one year during treatment with biologics, the patients' CRSwNP must be categorized as "partly controlled" as defined by presence of 1-2 of the following seven items (also available in EPOS 2020 table in protocol):

    1. Nasal blockage: present on most days of the week
    2. Rhinorrhoea/postnasal drip: mucopurulent on most days of the week
    3. Facial pain/pressure: present on most days of the week
    4. Sense of smell: impaired
    5. Sleep disturbance or fatigue: present
    6. Nasal endoscopy: diseased mucosa
    7. Rescue treatment (systemic , ESS, antibiotics): need of 1 course of rescue treatment

of which 1-5 will be scored by the patient using VAS (0-10) and noted above 5.

Exclusion criteria

Exclusion Criteria:

  • Patients with excellent response to biologics (0 of the above-mentioned 7 items for partly controlled disease)
  • Patients with no or limited response to biologics (>2 of the above-mentioned 7 items for partly controlled disease)
  • Patients with a cancer diagnosis deemed by the investigator to preclude participation in the trial
  • Patients who, because of language barriers, are not able to understand Danish written information and, thus, are not able to answer questionnaires
  • Patients who currently receive biologics for any other disease (asthma not included)
  • Patients who are not able to give (i.e., patients who are permanently incapable)
  • Patients who are not eligible because of the investigator's judgement
  • Patients who experience pregnancy during the study will be excluded after an unscheduled visit - active IVF treatment (please see below)
  • Unwillingness to follow the study procedure
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
135 participants (estimated)

Study arms

  • No intervention
    Standard dosing of biological therapy

    Continues dosing of mepolizumab (100 mg via injection pen, subcutaneous injection) or dupilumab (300 mg via injection pen, subcutaneous injection) every 4 weeks.

  • Active comparator
    Increased dosing interval of biological therapy

    Increases to a 6-week dosing interval at baseline - of mepolizumab (100 mg via injection pen, subcutaneous injection) or dupilumab (300 mg via injection pen, subcutaneous injection) - and if response to therapy is maintained, increases to 8-week dosing intervals at the follow-up visit in week 26. Thereafter, dosing every 8 weeks is maintained until the patient completes the trial at week 52.

    Drug: increased dosing interval of biological therapy

Interventions

  • Drugincreased dosing interval of biological therapy

    Increasing dosing interval of biological therapy for CRSwNP from every 4 weeks to every 6 weeks and if continued satisfactory response then to every 8 weeks.

This study also gives DupilumabStudies of DupilumabDupilumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. The percentage of patients achieving sustained partly controlled disease after tapering of biologics for CRSwNP

    "partly controlled" as defined by presence of 1-2 of the following 7 items: 1. Nasal blockage: present on most days of the week 2. Rhinorrhoea/postnasal drip: mucopurulent on most days of the week 3. Facial pain/pressure: present on most days of the week 4. Sense of smell: impaired 5. Sleep disturbance or fatigue: present 6. Nasal endoscopy: diseased mucosa 7. Rescue treatment (systemic corticosteroids, ESS, antibiotics): need of 1 course of rescue treatment

    Time frame: from enrollment (week 0) to week 52.

07

Study locations

3 of 9 sites recruiting
  • Dept of otorhinolaryngology, Aalborg University Hospital
    Aalborg, 9000, Denmark
    Not yet recruiting
    • Søren Pauli, MD · Contactsbro@rn.dk · 004597660000
    • Søren Pauli, MD · Principal investigator
  • Dept of otorhinolaryngology, head and neck surgery, Aarhus University Hospital
    Aarhus, 8200, Denmark
    Not yet recruiting
    • Kristian B Petersen, MD · Contactkrispete@rm.dk · 004578450000
    • Kristian B Petersen, MD · Principal investigator
  • Department of Otorhinolaryngology, Head and Neck Surgery & Audiology, Copenhagen University, Rigshospitalet
    Copenhagen, 2100, Denmark
    Recruiting
  • Esbjerg Og Grindsted Sygehus
    Esbjerg, 6700, Denmark
    Not yet recruiting
  • Dept of otorhinolaryngology, Gødstrup Regional Hospital
    Herning, 7400, Denmark
    Not yet recruiting
    • Adnan Madzak, MD · Contactadnan.madzak@auh.rm.dk · 004578439744
    • Adnan Madzak, MD · Principal investigator
  • Dept of otorhinolaryngology, Nordsjaellands Hospital
    Hillerød, 3400, Denmark
    Recruiting
  • Dept of otorhinolaryngology, Sjællands Universitetshospital
    Køge, 4600, Denmark
    Recruiting
    • Bent Ivan Larsen, MD · Contactbele@regionsjaelland.dk · 004547321401
    • Bent Ivan Larsen, MD · Principal investigator
  • Dept of otorhinolaryngology, Odense University Hospital
    Odense, 5000, Denmark
    Not yet recruiting
    • Anette Kjeldsen, MD, prof. · Contactanette.kjeldsen@rsyd.dk · 004565414314
    • Anette Kjeldsen, MD, prof · Principal investigator
  • Dept of otorhinolaryngology, Lillebaelt Hospital
    Vejle, 7100, Denmark
    Not yet recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Mar 2028, 32 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2025
First posted
Sep 23, 2025
StartActual
Jun 5, 2025
Primary completionEst.
Mar 1, 2028
CompletionEst.
Mar 1, 2028
Last update
Sep 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07187583
Responsible party
Elizabeth M. Stevens (national coordinating investigator, and sub-investigator at Rigshospitalet, Rigshospitalet, Denmark) — Principal investigator
First posted
Sep 23, 2025
Start date
Jun 5, 2025
Primary completion
Mar 1, 2028 (estimated)
Completion
Mar 1, 2028 (estimated)
Last update
Sep 23, 2025

Study contacts

Elizabeth M. Stevens Saporito, MD
Contact
este0027@regionh.dk
+4535452370
Christian von Buchwald, MD, DMSc, prof.
study director · Rigshospitalet, Dept. of Otorhinolaryngology, Head and Neck Surgery & Audiology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion